Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ADN1 - DE000A0Z23Q5 - Common Stock

88.5 EUR
+0.4 (+0.45%)
Last: 12/29/2025, 7:00:00 PM
Fundamental Rating

5

ADN1 gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 68 industry peers in the IT Services industry. Both the profitability and the financial health of ADN1 get a neutral evaluation. Nothing too spectacular is happening here. ADN1 is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

ADN1 had positive earnings in the past year.
ADN1 had a positive operating cash flow in the past year.
ADN1 had positive earnings in each of the past 5 years.
Each year in the past 5 years ADN1 had a positive operating cash flow.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

ADN1 has a worse Return On Assets (2.45%) than 63.24% of its industry peers.
ADN1's Return On Equity of 10.90% is in line compared to the rest of the industry. ADN1 outperforms 47.06% of its industry peers.
ADN1 has a worse Return On Invested Capital (5.23%) than 66.18% of its industry peers.
ADN1 had an Average Return On Invested Capital over the past 3 years of 3.16%. This is significantly below the industry average of 11.04%.
The 3 year average ROIC (3.16%) for ADN1 is below the current ROIC(5.23%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROIC 5.23%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

ADN1 has a Profit Margin of 0.99%. This is in the lower half of the industry: ADN1 underperforms 67.65% of its industry peers.
ADN1's Profit Margin has declined in the last couple of years.
ADN1's Operating Margin of 2.96% is on the low side compared to the rest of the industry. ADN1 is outperformed by 69.12% of its industry peers.
ADN1's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 85.30%, ADN1 is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
ADN1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

ADN1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ADN1 has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADN1 has more shares outstanding
The debt/assets ratio for ADN1 has been reduced compared to a year ago.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.62 indicates that ADN1 is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.62, ADN1 is doing good in the industry, outperforming 75.00% of the companies in the same industry.
The Debt to FCF ratio of ADN1 is 7.88, which is on the high side as it means it would take ADN1, 7.88 years of fcf income to pay off all of its debts.
ADN1 has a Debt to FCF ratio of 7.88. This is in the lower half of the industry: ADN1 underperforms 67.65% of its industry peers.
A Debt/Equity ratio of 1.60 is on the high side and indicates that ADN1 has dependencies on debt financing.
ADN1's Debt to Equity ratio of 1.60 is on the low side compared to the rest of the industry. ADN1 is outperformed by 76.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Altman-Z 3.62
ROIC/WACC0.94
WACC5.55%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.30 indicates that ADN1 should not have too much problems paying its short term obligations.
ADN1 has a Current ratio (1.30) which is comparable to the rest of the industry.
ADN1 has a Quick Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
ADN1's Quick ratio of 1.30 is fine compared to the rest of the industry. ADN1 outperforms 64.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 200.98% over the past year.
Measured over the past years, ADN1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -15.02% on average per year.
ADN1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.60%.
The Revenue has been growing by 23.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%

3.2 Future

ADN1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.75% yearly.
ADN1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.61% yearly.
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 27.74 indicates a quite expensive valuation of ADN1.
ADN1's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of ADN1 to the average of the S&P500 Index (26.84), we can say ADN1 is valued inline with the index average.
The Price/Forward Earnings ratio is 15.65, which indicates a correct valuation of ADN1.
ADN1's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of ADN1 to the average of the S&P500 Index (23.40), we can say ADN1 is valued slightly cheaper.
Industry RankSector Rank
PE 27.74
Fwd PE 15.65
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ADN1 is valued a bit cheaper than 67.65% of the companies in the same industry.
60.29% of the companies in the same industry are more expensive than ADN1, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.36
EV/EBITDA 6.58
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADN1's earnings are expected to grow with 63.28% in the coming years.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y76.08%
EPS Next 3Y63.28%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.85%, ADN1 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.41, ADN1 has a dividend in line with its industry peers.
With a Dividend Yield of 0.85, ADN1 pays less dividend than the S&P500 average, which is at 2.00.
Industry RankSector Rank
Dividend Yield 0.85%

5.2 History

The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

ADN1 pays out 31.75% of its income as dividend. This is a sustainable payout ratio.
ADN1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP31.75%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (12/29/2025, 7:00:00 PM)

88.5

+0.4 (+0.45%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-31 2026-03-31/amc
Inst Owners20.45%
Inst Owner ChangeN/A
Ins Owners50.28%
Ins Owner ChangeN/A
Market Cap577.90M
Revenue(TTM)2.10B
Net Income(TTM)20.84M
Analysts81.54
Price Target126.63 (43.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.85%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP31.75%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-10.47%
EPS NY rev (3m)-10.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE 27.74
Fwd PE 15.65
P/S 0.27
P/FCF 12.36
P/OCF 7.44
P/B 3.02
P/tB 11.41
EV/EBITDA 6.58
EPS(TTM)3.19
EY3.6%
EPS(NY)5.65
Fwd EY6.39%
FCF(TTM)7.16
FCFY8.09%
OCF(TTM)11.9
OCFY13.44%
SpS322.11
BVpS29.27
TBVpS7.75
PEG (NY)0.33
PEG (5Y)N/A
Graham Number45.84
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROCE 11.91%
ROIC 5.23%
ROICexc 5.78%
ROICexgc 8.22%
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
FCFM 2.22%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Debt/EBITDA 2.26
Cap/Depr 42.37%
Cap/Sales 1.47%
Interest Coverage 5.03
Cash Conversion 57.42%
Profit Quality 224.33%
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z 3.62
F-Score7
WACC5.55%
ROIC/WACC0.94
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%
EBIT growth 1Y38.36%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year304.77%
EBIT Next 3Y78.82%
EBIT Next 5Y44.55%
FCF growth 1Y300.77%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y1010.67%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


What is the valuation status of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


What is the profitability of ADN1 stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What is the valuation of ADESSO SE based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADESSO SE (ADN1.DE) is 27.74 and the Price/Book (PB) ratio is 3.02.


Is the dividend of ADESSO SE sustainable?

The dividend rating of ADESSO SE (ADN1.DE) is 4 / 10 and the dividend payout ratio is 31.75%.